STATEMENT: After Years Of Advocacy, Patients Will See Long-Awaited Relief From Eli Lilly’s Insulin Price Cut
“It’s Time For The Other Big Insulin Corporations To Follow Suit”
ICYMI: Q&A With P4AD’s Executive Director Merith Basey
Patient Advocate Lisa Ann Wetzel-Trainor Moderated A Conversation Where Merith Answered Questions On Her Background, The Inflation Reduction Act, And P4AD’s Future Goals:
STATEMENT: Unjustified Price Of New ALS Treatment Reinforces Fact That Our Drug Pricing System Fails The People It Is Supposed To Serve – Patients
The following statement was issued by David Mitchell, a cancer patient and founder and president of Patients For Affordable Drugs, in response to the pricing of Relyvrio following the Food and Drug Administration’s approval of the drug combination to treat amyotrophic lateral sclerosis (ALS):
Bob’s Story
My name is Bob Parant, and I have been living with type 1 diabetes for 50 years. I am one of the 3.3 million Medicare beneficiaries who need insulin. I was diagnosed during what I call the “dark ages” of diabetes and have had many challenges along the way, including losing my leg.
Merith Basey Named Executive Director Of Patients For Affordable Drugs
Basey Has Devoted Her Career To Ensuring That Life-saving Medications Are Affordable And Accessible For All Who Need Them
Jackie’s Story
My name is Jackie Trapp. I live in Muskego, WI and have been married for 34 years to my wonderful, loving husband. In August of 2015, I was diagnosed with multiple myeloma, an incurable blood cancer.
Steven’s Story
My name is Steven Hadfield. I am 70 years old, a long-time North Carolinian, a husband, a grandfather of three, and a football fanatic. I’m also a rare cancer and type 2 diabetes patient.
JULY PRICE HIKES REPORT: Big Pharma’s Continued Greed Underscores Urgent Need For Reform To Lower Drug Prices
In The Third Year Of The Pandemic And As Americans Grapple With Record Inflation, Big Pharma Continues To Raise Prices And Exploit Patients
